Stapled Anticancer Peptides via Linker Birradical

The patent applies parameter changes by modifying the peptide sequence parameters (amino acid composition, length, charge) and structural parameters (secondary structure content, compactness) to achieve both high anticancer activity and improved specificity/sensitivity. The optimized sequences represent specific parameter configurations that resolve the contradiction between general activity and precise targeting.

The patent creates composite peptide structures by combining different amino acid motifs and structural elements within a single peptide sequence. These composite designs integrate cell-penetrating domains, tumor-targeting motifs, and cytotoxic modules to achieve multifunctional peptides that simultaneously provide broad anticancer activity with enhanced specificity for cancer cells.

The patent applies local quality by designing peptides with differentiated functional regions: N-terminal domains for cell penetration and targeting with high specificity to cancer cells, and C-terminal domains for cytotoxic activity. This spatial differentiation of function allows the peptide to exert strong anticancer effects at the target site while minimizing off-target toxicity, as the toxic moiety is only activated upon specific binding to cancer cell components.

The patent designs peptides with controlled stability characteristics - sufficiently stable to reach the target and exert effect, but designed to be degraded after use. The peptides incorporate amino acid sequences that are susceptible to proteolytic cleavage after fulfilling their anticancer function, ensuring they do not accumulate to toxic levels and are rapidly cleared from the system, thus reducing long-term side effects.